X

CTS History

01Dec

Babesia

In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.

About the Author

Related

CTS merges with the three Red Cross testing laboratories

CTS merges with the three Red Cross testing laboratories

CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...

Read More >
Source Plasma / Blood Donor Testing

Source Plasma / Blood Donor Testing

In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).

Read More >

Research Consortium

CTS Research Consortium was established to further CTS’s leadership in infectious disease research....

Read More >
CTS implements licensesd Zika test

CTS implements licensesd Zika test

Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...

Read More >
CTS Business Continuity Plan

CTS Business Continuity Plan

As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...

Read More >
CTS Founded

CTS Founded

In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...

Read More >